Investing
Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)
Published:
Last Updated:
We are seeing massive gap-ups this morning in stem cell stocks. President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding. What is interesting here is that this is not really new news other than the timing and the formality. The following prices are as of 8:19 AM EST.
- Aastrom Biosciences Inc. (NASDAQ: ASTM) +87% at $0.62
- Cytori Therapeutics Inc. (NASDAQ: CYTX) +38% at $3.20
- Geron Corp. (NASDAQ: GERN) +29% at $4.99
- Neostem Inc. (AMEX: NBS) NOT TRADED
- Osiris Therapeutics Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
- StemCells Inc. (NASDAQ: STEM) +55% at $2.15
- Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57
Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.
JON C. OGG
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
